Baseline characteristics of patients receiving NAs for AE of CHB.

AIH, autoimmune hepatitis; ALD, alcoholic liver disease; ALT, alanine aminotransferase; DM, diabetes mellitus; ETV, entecavir; HAV, hepatitis A virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; HE, hepatic encephalopathy; HEV, hepatitis E virus; HIV, Human immunoddficiency virus; LAM, lamivudine; LDT, telbivudine; NA, not available; NAs, nucleos(t)ide analogues; PT, prothrombin time; TB, serum total biliruin; ULN, upper limit of normal.†Of 10 enrolled, 6 patients with dose of LAM 300 mg/day, 4 had undergone interferon or corticosteroid treatment for liver disease.††Patients had comorbid illnesses in both groups.*Dose of LAM 150 mg/day; otherwise the doses of drugs were as follows: LAM 100 mg/day, ETV 0.5 mg/day, LDT 600 mg/day.**IgM anti-HBc seronegative patients were recruited as control group.‡Patients without AE were recruited as control group, and subset data on 45 patients with AE were abstracted.♂15 patients with SAE were treated with LAM 300 mg/day for only a short term at the start of therapy.♂♂ 38.3% and 4.8% of patients had exposed to LAM and had definitely LAM resistance before enrolment, 104 were examined for HBV genotypes.○ Detection limit for HBV DNA was 100 copies/ml for calculation.